First Opinion By Antje M. Barreveld As a pain specialist, I may have caused more harm by underprescribing opioids
Health By Andrew Joseph With overdoses at record highs, a veterinary tranquilizer spreading through the U.S. drug supply poses new threats
Health By Andrew Joseph In a victory for pain experts, CDC tones down its opioid prescribing guidelines
First Opinion By Paul Pelletier and Beth Macy After ‘startling rebuke’ of multibillion-dollar bankruptcy settlement, ‘these Sacklers don’t deserve a pass — again’
First Opinion By Mason Marks FDA’s kratom ban would harm the public and damage the agency’s credibility
Exclusive By Shraddha Chakradhar and Casey Ross The history of OxyContin, told through unsealed Purdue documents
First Opinion By Stefan G. Kertesz and Kate M. Nicholson No more ‘shortcuts’ in prescribing opioids for chronic pain. Millions of Americans need nuanced care
First Opinion By Shravani Durbhakula and Joshua M. Sharfstein HHS needs to step up so CDC’s new guidelines won’t be ‘a bridge to nowhere’ for most Americans living with chronic pain
Pharmalot By Ed Silverman Pharmalittle: Amgen faces $7B IRS back-tax bill and fine; McKinsey exec apologizes for opioid work during hearing
Pharmalot By Ed Silverman Endo wins a reprieve in an opioid lawsuit in Tennessee as appeals court overturns sanctions
Pharmalot By Elizabeth Cooney Pharmalittle: Advisory panel narrowly votes down ALS drug; Vertex looks to advance experimental pain drug
Pharmalot By Ed Silverman CVS, Teva, Allergan and Endo reach $878 million deal with Florida over the opioid crisis
First Opinion By John C. Messinger, Anand Chukka and J. Wesley Boyd The case for decriminalizing the street sale of buprenorphine
Pharmalot By Ed Silverman Teva and Allergan reach $107 million deal with Rhode Island over opioid crisis
First Opinion By Emma Biegacki Emergency response systems must not overlook people with substance use disorders
Pharma By Geoff Mulvihill and Jennifer Peltz — Associated Press ‘Scum of the earth’: Opioid crisis victims face Purdue Pharma owners
Pharmalot By Ed Silverman Dozens of towns and counties object to ‘hush money’ tied to Purdue opioid settlement
Pharmalot By Ed Silverman Pharmalittle: Insurers balk at opioid payouts to drugmakers and wholesalers; AbbVie settles another Humira biosimilar lawsuit
Health By Andrew Marquardt — Medill News Service Doctors, companies push to keep looser, pandemic-era rules for prescribing opioid addiction treatment via telemedicine
Pharmalot By Ed Silverman Sacklers agree to $6 billion Purdue bankruptcy settlement over opioid crisis
Health By Andrew Joseph Supreme Court debates exactly when a doctor’s misprescribing becomes criminal
Pharmalot By Ed Silverman Tennessee judge sanctions Endo for withholding opioid documents, refuses to recuse himself from case
Pharmalot By Ed Silverman Johnson & Johnson, three pharma wholesalers finalize $26 billion opioid crisis settlement
Pharmalot By Ed Silverman Lawmakers ask Justice Department to explore criminal charges against Sacklers
Health By Andrew Joseph Fight over opioid prescribing — and when it turns criminal — heads to Supreme Court
Pharmalot By Ed Silverman Pharmalittle: Gilead to pay $1.25B to settle HIV patent row with Glaxo; Native American tribes strike $590M deal over opioid crisis
Pharmalot By Ed Silverman Native American tribes reach $590 million deal with J&J and three wholesalers over the opioid crisis
First Opinion By Donald Norcross Opioid overdoses are killing Americans. Improving access to methadone can save lives
First Opinion By Paul J. Joudrey and Adam J. Gordon Inflexible methadone regulations impede America’s efforts to reduce overdose deaths